News

October 2017

Viewing posts from October , 2017

Nextremity Solutions, Inc. Announces Full U.S. Commercial Launch of the Arcus™ Staple System

Warsaw, Indiana, October 25, 2017 — Nextremity Solutions, Inc., a strategic commercialization organization with a focus on the musculoskeletal space, located in “The Orthopedic Capital of the World,” Warsaw, Ind., today announced the full release of the Arcus™ Staple System through its strategic alliance with Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare.

In October 2016, Zimmer Biomet announced an exclusive agreement with Nextremity Solutions to globally distribute the company’s foot and ankle deformity correction products. The initial three products to be distributed through this alliance included the Nextra® Hammertoe Correction System, Re+Line® Bunion Correction System, and the MSP™ Metatarsal Shortening System. Nextremity Solutions’ Arcus Staple System is the latest product to be added to Zimmer Biomet’s foot and ankle portfolio as part of this agreement.

During clinical trials, more than 200 Arcus staples were implanted during surgeries performed in facilities around the U.S.  During this micro-commercialization phase, Nextremity Solutions’ i3TM Strategic Solutions process was used to assess valuable surgeon feedback that led to improvements of the implant and instrumentation design.  The Arcus staple’s innovative arc design has been shown to provide greater and more sustained compression compared to competitive staples.1

  1. A Mechanical Evaluation of the Interfragmentary Compressive Forces of the Arcus Staple System, Lisa A. Ferra, Ph.D., Orthokinetic Technologies and Orthokinetic Testing Technologies, Southport, NC

About Nextremity Solutions, Inc.

Nextremity Solutions, Inc. is a privately held strategic commercialization organization with a focus on the musculoskeletal space, offering innovative solutions and Revenue Ready™ products for various musculoskeletal applications and for the benefit of our industry partners. The Company’s procedure-ready, sterile implant systems include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.

Nextremity Solutions, Inc. Announces Limited Release of the Axi+Line™ Proximal Bunion Correction System

Nextremity Solutions, Inc., a strategic commercialization organization with a focus on the musculoskeletal space, located in “The Orthopedic Capital of the World” Warsaw, IN, is announcing the limited release of its newest product, the Axi+Line™ Proximal Bunion Correction System for the treatment of hallux valgus deformity, also known as a bunion. This announcement comes shortly after Nextremity Solutions announced the limited release of another new product, the PiroVue™ Gastrocnemius Recession System for the treatment of equinus deformities in patients.

According to a 2015 study in Foot & Ankle International® entitled, “A New Measure of Tibial Sesamoid Position in Hallux Valgus in Relation to the Coronal Rotation of the First Metatarsal in CT Scans”, patients with hallux valgus deformities (bunions) had a “more pronated first metatarsal than the control group”. The study showed that 87.3% of the patients sampled with hallux valgus deformity also had abnormal frontal plane rotation of the first ray.

Nextremity Solutions currently offers the Re+Line® Bunion Correction System, which specifically focuses on the treatment of hallux valgus deformities of lesser angles. However, the Axi+Line Proximal Bunion Correction System addresses treatment of deformities of larger angles and addresses correction in the frontal plane.

“The Axi+Line Proximal Bunion Correction System is a reproducible, guided, and fully disposable system for addressing hallux valgus deformities via a proximal metatarsal approach.  This system takes advantage of the modified Mau osteotomy and addresses the concerns of rotational correction in the frontal plane while simultaneously reducing the hallux valgus angle.  It provides surgeons with a great option between a distal approach and a Lapidus approach.  We’re excited about the introduction of Axi+Line as well as our soon-to-launch Lapidus system,” commented Ryan D. Schlotterback, Chief Commercial Officer for Nextremity Solutions, Inc.

The patent-pending Axi+Line Proximal Bunion Correction System will utilize a limited launch with key surgeons prior to a full commercial launch in 2018.

For more information or to schedule a demonstration of the Axi+Line Proximal Bunion Correction System, please visit http://www.nextremity.com/axiline.

 

About Nextremity Solutions, Inc.

Nextremity Solutions, Inc. is a privately held strategic commercialization organization with a focus on the musculoskeletal space, offering innovative solutions and Revenue Ready™ products for various musculoskeletal applications and for the benefit of our industry partners. The Company’s procedure-ready, sterile implant systems include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.

For further information, visit www.nextremitysolutions.com or call Dave Temple, Executive Director, i3 Direct at 574-635-3022.